New Weight-Loss Pill Beats Oral Wegovy in Major Trial

In a major development for obesity and metabolic health treatment,Eli Lilly’s experimental oral GLP-1 therapy, orforglipron, demonstrated superior results compared withoral semaglutide (Wegovy)in a largePhase 3 head-to-head trialinvolving nearly 1,700 participants with type 2 diabetes and overweight conditions. TheACHIEVE-3study, published...